期刊
EXPERIMENTAL NEUROLOGY
卷 327, 期 -, 页码 -出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.expneurol.2020.113219
关键词
Astroeytes; Motor neurons; Nicotinamide riboside; NMNAT2; SIRT3; SIRT6
资金
- NIH [R01NS089640]
- Swiss National Science Foundation [310030B-160318]
- [P30 CA138313]
- [P20 GM103542]
- [S10 OD018113]
- Swiss National Science Foundation (SNF) [310030B_160318] Funding Source: Swiss National Science Foundation (SNF)
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS089640] Funding Source: NIH RePORTER
Amyotrophic lateral sclerosis (ALS) is characterized by progressive degeneration of motor neurons. Astrocytes from diverse ALS models induce motor neuron death in co-culture. Enhancing NAD(+) availability, or increasing the expression of the NAD(+)-dependent deacylases SIRT3 and SIRT6, abrogates their neurotoxicity in cell culture models. To determine the effect of increasing NAD(+) availability in ALS mouse models we used two strategies, ablation of a NAD(+)-consuming enzyme (CD38) and supplementation with a bioavailable NAD(+) precursor (nicotinamide riboside, NR). Deletion of CD38 had no effect in the survival of two hSOD1-linked ALS mouse models. On the other hand, NR-supplementation delayed motor neuron degeneration, decreased markers of neuroinflammation in the spinal cord, appeared to modify muscle metabolism and modestly increased the survival of hSOD1 G93A mice. In addition, we found altered expression of enzymes involved in NAD(+) synthesis (NAMPT and NMNAT2) and decreased SIRT6 expression in the spinal cord of ALS patients, suggesting deficits of this neuroprotective pathway in the human pathology. Our data denotes the therapeutic potential of increasing NAD(+) levels in ALS. Moreover, the results indicate that the approach used to enhance NAD(+) levels critically defines the biological outcome in ALS models, suggesting that boosting NAD(+) levels with the use of bioavailable precursors would be the preferred therapeutic strategy for ALS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据